Picture loading failed.

Anti-APP therapeutic antibody (Pre-made Donanemab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Donanemab (USAN; development code LY3002813) is a biological drug in trial to treat early symptoms of Alzheimer's disease. There is no cure or treatment for Alzheimer��s disease. Donanemab has shown positive results in Eli Lilly and Co.��s first two trials. Donanemab was developed by the company Eli Lilly and Co, used in past and current trials as a possible source of treatment for the heterogeneous condition Alzheimer��s disease. Donanemab, also known as N3pG, is an antibody produced in mice that targets an abnormal protein, amyloid beta (A��), that is produced in the bone marrow. Whilst the cause of Alzheimer��s disease is still unknown, great advances in amyloid pathology has led to a relation between the quantity of A�� peptides and the development in Alzheimer's disease. A�� peptides are deposited in the brain and when in excess will bind together to create a protein plaque. Donanemab targets this protein plaque, clearing the excess protein which causes a burden in the brain.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-153-1mg 1mg 3090
GMP-Bios-ab-153-10mg 10mg 21890
GMP-Bios-ab-153-100mg 100mg 148000
GMP-Bios-ab-153-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-APP therapeutic antibody (Pre-made Donanemab biosimilar,Whole mAb)
INN Name Donanemab
TargetAPP
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesEli Lilly
Conditions Approvedna
Conditions ActiveAlzheimer's disease
Conditions Discontinuedna
Development Techna